Deciphering Activity in Early Facial Vitiligo: A Case Report Integrating Clinical, Wood's Lamp, and Dermoscopic Findings

Rina Gustia[1], Mutia Sari[1], Afifah Alfyanita[1]*

[1]Department of Dermatology, Venereology, and Aesthetics, Faculty of Medicine, Universitas Andalas/Dr. M. Djamil General Hospital, Padang, Indonesia

A B S T R A C T

Background: The management of non-segmental vitiligo hinges on accurately assessing disease activity to guide appropriate therapy. A clinical challenge arises in patients presenting with a low vitiligo area scoring index (VASI), suggesting limited disease, which may be discordant with underlying inflammatory activity, potentially leading to therapeutic inertia. **Case presentation:** A 34-year-old woman with Fitzpatrick skin type III presented with a two-month history of rapidly progressing facial vitiligo, preceded by an erythematous phase. Despite a low VASI score of 1, the patient-reported vitiligo disease activity (VIDA) score was +4. Dermoscopy was instrumental, revealing definitive in-vivo evidence of inflammation and instability, including a pinkish background, telangiectasias, and a reversed pigment network. Based on this discordance between disease extent and activity, a multi-modal therapeutic regimen was initiated. A six-month follow-up demonstrated disease stabilization and significant perifollicular repigmentation, with resolution of the inflammatory dermoscopic signs. **Conclusion:** This case report illustrates the critical importance of an integrated diagnostic approach that moves beyond area-based assessment. It highlights how dermoscopy, when used to resolve the clinical paradox of low-extent but high-activity disease, can serve as an objective biomarker to justify timely and robust immunomodulatory intervention. This approach is crucial for altering the disease trajectory and optimizing patient outcomes.

1. Introduction

Non-segmental vitiligo stands as the most prevalent depigmenting disorder encountered in dermatological practice, affecting up to 2% of the world's population across all ethnicities and skin types.[1] It is a chronic, often progressive condition defined by the selective destruction of functional melanocytes within the epidermis and hair follicles. This cellular loss manifests as well-demarcated, asymptomatic, milky-white macules and patches that can develop on any cutaneous surface.[2] While vitiligo does not impart physical morbidity in the traditional sense, its profound impact on appearance, particularly when affecting cosmetically sensitive

areas like the face and hands, precipitates significant psychological distress, social stigmatization, and a severely diminished quality of life. Consequently, the clinical management of vitiligo extends beyond mere cosmesis; it represents a critical intervention to restore not only pigment but also patient self-esteem and psychosocial well-being. The therapeutic landscape of vitiligo is fundamentally dichotomous, predicated entirely on the biological state of the disease at a given point in time.[3] The central clinical task is to distinguish between "stable" vitiligo, where the disease process is quiescent, and "unstable" or "active" vitiligo, where an ongoing pathological process is actively destroying melanocytes.[4] In stable disease,

3254

the therapeutic goal is repigmentation, employing strategies designed to stimulate the proliferation and migration of surviving melanocytes from reservoirs within the hair follicles. Conversely, in active disease, the primary, urgent goal is to arrest the progression by suppressing the underlying destructive process. Only once stability is achieved can repigmentation be effectively pursued. This critical distinction dictates all subsequent therapeutic choices, from topical agents to systemic immunomodulators and phototherapy. An error in this initial assessment—mistaking active disease for stable—can lead to ineffective treatment and, more importantly, allow for the irreversible loss of the follicular melanocyte reservoir, permanently compromising the potential for future repigmentation.[5]

Historically, the assessment of activity has relied on a constellation of clinical signs and patient reporting. The appearance of new lesions, the enlargement of existing ones, the presence of trichrome borders (a transitional zone of hypopigmentation), confetti-like depigmentation, and the Koebner phenomenon (the development of lesions at sites of trauma) are all recognized indicators of instability.[6] Tools like the Vitiligo Disease Activity (VIDA) score have been developed to standardize the patient's history of progression. However, these methods are fraught with limitations. Clinical signs are not universally present, and the VIDA score, while valuable, relies on the accuracy and subjectivity of patient recall. This creates a frequent and vexing clinical dilemma. A patient may present with a very small area of involvement, yielding a low vitiligo area scoring index (VASI) that suggests "mild" disease.[7] Yet, the same patient may give a history of explosive growth, resulting in a high VIDA score. In this scenario of discordant metrics, the clinician is faced with a difficult choice. Does one adopt a conservative approach based on the limited area, risking further progression? Or does one initiate aggressive systemic therapy based on the history, potentially overtreating the patient? It is within this crucible of clinical uncertainty that modern diagnostic technologies have

become essential. The Wood's lamp, which utilizes long-wave ultraviolet A (UVA) light, has long been a cornerstone of the vitiligo workup.[8] By causing the porphyrins in collagen to fluoresce, it creates a contrast that makes depigmented skin, which lacks the UV-absorbing properties of melanin, appear brilliant, chalky-white. This is invaluable for confirming true depigmentation and delineating the full extent of lesions, especially in individuals with fair skin. However, the Wood's lamp is a static tool; it reveals the absence of pigment but offers little insight into the biological activity or inflammation occurring at the lesion's edge.

Dermoscopy has revolutionized this aspect of care. This non-invasive technique of in-vivo skin surface microscopy, using magnification and specialized illumination, bridges the chasm between clinical morphology and histopathology.[9] It allows the clinician to visualize subsurface structures and patterns invisible to the naked eye, providing direct morphological correlates of the ongoing cellular and vascular events. In vitiligo, dermoscopy has proven to be an exceptionally powerful tool for assessing disease activity. A rich semiology has been established: the presence of a well-defined, reticular pigment network at the border and perifollicular hyperpigmentation are reliable signs of stability or repigmentation. Conversely, signs of instability include blurred or ill-defined borders, the presence of a "reversed pigment network," micro-Koebner phenomena (small, satellite depigmented dots), and, most critically, the signs of underlying inflammation—a diffuse pinkish or erythematous background and the presence of telangiectasias. These vascular patterns are the direct visualization of the inflammatory infiltrate and cytokine-mediated vasodilation that drive the disease process. Despite the established utility of these tools, a practical gap persists in the literature concerning their integrated application to solve specific, high-stakes clinical problems. The novelty of this report, therefore, is not in merely presenting a case where multiple diagnostic tools were used. Rather, its specific and unique contribution is to provide a

detailed, longitudinal analysis of a common and challenging clinical dilemma: the management of a patient with profoundly discordant VASI and VIDA scores.[10] This case report aims to meticulously document the clinical reasoning process in such a scenario. We seek to demonstrate how dermoscopy can be employed as the decisive biomarker to resolve this clinical paradox, providing objective, in-vivo evidence of subclinical inflammation that can robustly justify the initiation of prompt, aggressive, and mechanism-based immunomodulatory therapy, a decision that might otherwise be delayed due to the deceptively limited area of involvement.

2. Case Presentation

A 34-year-old woman, a high school teacher and mother of two with Fitzpatrick skin type III, presented to the Dermatology Clinic at Dr. M. Djamil General Hospital. Her demeanor was anxious, and she carried a folder of printed internet articles about skin conditions. Her chief complaint was the recent and rapid appearance of "white spots" on her face, which were causing her significant distress. She recounted the timeline of her condition with meticulous detail. The first change occurred approximately three months prior, not as a white spot, but as a persistent, faint pinkish rash on her right cheek, which she initially dismissed as a minor irritation. She noted that after spending an afternoon at her children's outdoor sporting event, the area became noticeably redder and slightly swollen, a reaction she had never experienced before. Over the next few weeks, she observed a similar pinkish patch developing on her left cheek. Then, the evolution began. She described watching, with growing alarm, as the center of the original pink patch on her right cheek "faded to a stark, unnatural white." This process, she reported, took about a week. Shortly thereafter, the same transformation occurred on her left cheek. The most alarming phase began in the six weeks immediately preceding her consultation. During this period, she reported an "explosion" of new lesions. Small white macules appeared almost simultaneously on her forehead just above the

eyebrows, on the bridge of her nose, and on her philtrum. She stated that she could "almost see them getting bigger day by day." The lesions themselves were entirely asymptomatic; she emphatically denied any itch, pain, burning, or numbness, which she had read could be associated with other skin conditions. Her primary concern was cosmetic, but it was deeply affecting her. She admitted to avoiding social gatherings and found herself constantly applying makeup in an unsuccessful attempt to conceal the patches, which she felt made her look "unwell and strange."

The patient's past medical history was notable for axial myopia (nearsightedness) since adolescence, for which she wore glasses intermittently. She reported a year-long history of increasing photophobia and a subjective feeling of "hazy" or blurred vision, which she had attributed to her uncorrected refractive error. However, given the potential for vitiligo to be associated with ocular inflammatory conditions, a formal ophthalmological consultation was immediately arranged. This comprehensive evaluation included visual acuity testing, intraocular pressure measurement, and a detailed, dilated funduscopic and slit-lamp examination. The ophthalmologist confirmed her known axial myopia but definitively ruled out any signs of active or past inflammation. There was no evidence of keratic precipitates, anterior chamber cells or flare, synechiae, or vitritis, effectively ruling out conditions such as vitiligo-associated uveitis or Vogt-Koyanagi-Harada (VKH) syndrome. Her personal and family histories were thoroughly explored and were negative for vitiligo, psoriasis, thyroid disease, pernicious anemia, type 1 diabetes, or any other autoimmune or endocrine disorders. She was not taking any regular medications. A detailed inquiry into her lifestyle revealed several potentially relevant factors. She described herself as an "outdoors person" on weekends but admitted to rarely using sunscreen, believing her olive complexion was protective. Her daily facial hygiene was basic, consisting of washing with a standard liquid body soap and drying her face by vigorously rubbing it with a cotton towel. This

history of chronic, unprotected UV exposure and repetitive mechanical trauma was noted. A comprehensive analytical summary of her history, cross-referenced with its potential pathophysiological significance, is presented in Figure 1.


Figure 1. Analytical summary of the patient's history and potential pathophysiological implications.

A full-body cutaneous examination was performed. The patient's face displayed multiple, asymmetrically distributed, non-palpable macules located on the forehead, periorbital (eyebrows), malar (cheeks), nasal, and perioral regions. The lesions were characterized by a striking heterogeneity. There were several well-demarcated, "chalk-white" depigmented macules, representing established disease. Surrounding these were less-defined, hypopigmented macules, suggesting a transitional state. Critically, along the advancing borders of the lesions on her cheeks and forehead, a subtle but definite erythema was observed, giving the periphery a faint pinkish hue. Palpation of the lesions revealed no induration or atrophy. A meticulous examination of the hair follicles within the patches was conducted using a magnifying lamp, which revealed several white hairs (leukotrichia) within the depigmented patches on her eyebrows, a finding with significant prognostic implications. To move beyond qualitative description, a quantitative assessment was performed to objectively stage the disease and its impact. The results, detailed in Figure 2, immediately brought the central clinical paradox into sharp focus. The vitiligo area scoring index (VASI) was calculated by estimating the percentage of depigmentation within each facial unit (forehead, perioral, etc.) and applying the standardized formula. The final VASI score was 1, a low value indicating that less than 2% of her facial skin was affected. In stark contrast, the Vitiligo Disease Activity (VIDA) score was determined. Based on her unequivocal history of new lesion formation and the enlargement of existing lesions within the preceding 6 weeks, she was assigned a VIDA score of +4, the highest level of activity. The Dermatology Life Quality Index (DLQI) was administered, yielding a score of 12. A breakdown of the questionnaire revealed that the highest scores were for the questions related to feelings of self-consciousness ("feeling embarrassed or self-conscious because of your skin") and the interference with social or leisure activities, confirming the moderate but significant impact on her life.

Baseline Clinical Presentation and Quantitative Assessment

Clinical picture on the patient. On facial examination, the patient presented with multiple lesions, including hypopigmented macules (blue circle), depigmented macules (black circle), and erythematous macules (red circle), located around both eyebrows, cheeks, nose, and upper lip.

Lesion Morphology

Depigmented, hypopigmented, and erythematous macules; leukotrichia.

Clinical Significance

The combination of morphologies, particularly erythema, strongly suggested an active, inflammatory process. Leukotrichia implied deep follicular involvement.

VASI Score

1

Clinical Significance

Quantified the limited surface area of involvement, creating a clinical paradox when juxtaposed with activity signs.

VIDA Score

+4

Clinical Significance

Objectified the patient's history of rapid progression, providing a strong indication for immediate immunomodulatory therapy.

DLQI Score

12

Clinical Significance

Confirmed a moderate, clinically significant impact on the patient's quality of life, underscoring the need for effective intervention.

Figure 2. Summary of clinical examination and quantitative scoring at baseline.

To definitively resolve the clinical paradox presented by the discordant VASI and VIDA scores, and to visualize the underlying pathology, ancillary investigations were performed. The patient was taken to a darkened examination room, and a Wood's lamp was used to illuminate her face. Under the 365 nm UVA light, the depigmented macules fluoresced a brilliant, stark, chalky-white, confirming the complete loss of epidermal melanin. The hypopigmented areas showed a less intense but still enhanced fluorescence, and the borders of all lesions appeared more sharply demarcated than under visible light, allowing for a more accurate assessment of their true extent.The pivotal investigation was dermoscopy. Using a handheld dermoscope (Dermlite DL3, 10x magnification, polarized mode), multiple representative lesions were examined. The ancillary diagnostic findings presented in Figure 3 provide a comprehensive and multi-layered narrative of the patient's vitiligo, moving beyond the simple clinical appearance to reveal the underlying biological activity and structural changes within the skin. The investigation begins with the Wood's lamp examination, a foundational tool in pigmentary disorders. As depicted, the application of long-wave ultraviolet light dramatically enhances the visibility of the lesions, causing them to emit a characteristic, bright, milky-white fluorescence. This phenomenon is not merely for visualization; it is a definitive diagnostic confirmation. It works on the principle of optical contrast: healthy skin containing melanin absorbs the UV light, appearing dark, whereas the vitiliginous skin, devoid of melanin, reflects the light, resulting in the stark, glowing appearance. This finding is critically important as it confirms a state of true depigmentation (complete absence of melanin), allowing the clinician to confidently differentiate the condition from various hypopigmentary disorders where some melanin might persist. While the Wood's lamp confirms *what* the condition is, the dermoscopy examination, also shown in Figure 3, reveals *how* the disease is behaving. This non-invasive microscopic technique uncovers the intricate details of the disease process at the cellular

and vascular level. The presence of whitish structureless areas is the most fundamental finding, representing the dermoscopic hallmark of established vitiligo. This uniform, barren-white landscape corresponds to the "optical void" left by the complete destruction of melanocytes in the epidermis. It signifies the end-stage of the disease in that specific location. However, the most crucial insights come from the signs of active disease. The observation of telangiectasias on a pinkish background is a direct, in-vivo visualization of an active inflammatory milieu. This is not a passive finding; it is the microscopic evidence of the autoimmune battle taking place in the skin. The pinkish hue reflects dermal inflammation and increased blood flow, while the fine, linear red vessels (telangiectasias) are dilated capillaries, a response to the release of pro-inflammatory cytokines like TNF-α and IL-1 by the autoreactive T-cells attacking the pigment cells. This finding single-handedly shifts the clinical paradigm from treating a simple loss of color to managing an active, inflammatory dermatosis. Furthermore, the presence of a reversed pigment network serves as a specific marker of active disease progression. In healthy skin, a normal pigment network is seen, with pigment concentrated in the rete ridges. In active vitiligo, the autoimmune attack often targets these interfollicular melanocytes first, while the melanocytes deeper within the hair follicles are transiently spared. This results in a "reversed" or "inverse" pattern where pigment is lost from the network but remains around the follicular openings. Observing this sign at the lesion's border is a clear indication that the wave of depigmentation is actively advancing. Finally, the finding of leukotrichia, or white hairs within the vitiligo patch, carries significant prognostic weight. The hair follicle bulge acts as the primary reservoir for melanocyte stem cells, which are essential for treatment-induced repigmentation. Leukotrichia signifies that the inflammatory attack has been so intense and deep that it has successfully destroyed this vital stem cell reservoir. Consequently, the potential for repigmentation originating from these affected follicles

is drastically reduced or eliminated, signaling a poorer prognosis for cosmetic recovery in that specific area. Figure 3 masterfully tells the complete story of the patient's condition. The Wood's lamp confirms the nature of the pigment loss, while dermoscopy provides a dynamic, four-part assessment: the extent of established damage (whitish areas), the intensity of the current inflammatory attack (pinkish background and telangiectasias), the direction of spread (reversed pigment network), and the long-term prognosis for recovery (leukotrichia).

Ancillary Diagnostic Findings at Baseline

Wood's lamp examination reveals milky-white fluorescence on the lesion, confirming true depigmentation.

Dermoscopy examination shows whitish structureless areas (blue arrow), reversed pigment network (purple arrow), leukotrichia (orange arrow), and telangiectasia (black arrow), on a pinkish background. (Dermlite DL3, 10x magnification)

Pathophysiological Correlation of Dermoscopic Findings

Whitish Structureless Areas

The dermoscopic hallmark of established vitiligo, representing the "optical void" left by the absence of melanin pigment in the epidermis.

Telangiectasias on a Pinkish Background

Direct in-vivo evidence of an active inflammatory milieu. Correlates with vasodilation driven by pro-inflammatory cytokines and reflects the infiltration of autoreactive T-cells.

Reversed Pigment Network

A specific marker of active progression. Represents the preferential destruction of interfollicular melanocytes, while pigment is transiently retained in the more protected perifollicular areas.

Leukotrichia

Confirmed destruction of the melanocyte stem cell reservoir within the hair follicle bulge. A significant negative prognostic indicator for repigmentation in the affected follicles.

Figure 3. Summary of ancillary diagnostic findings at baseline.

The synthesis of these findings was unequivocal. The patient's history (VIDA +4) indicated rapid progression. The clinical examination revealed inflammatory signs (erythema) and poor prognostic markers (leukotrichia). The dermoscopic examination provided the definitive "smoking gun": objective, real-

time evidence of a significant underlying inflammatory process (pinkish background, telangiectasias) and active marginal progression (reversed pigment network). The low VASI score was thus recontextualized not as a sign of mild disease, but as a measurement taken at a very early point in an explosive disease course. This comprehensive, integrated analysis resolved the clinical paradox and provided a robust, evidence-based rationale for initiating immediate and aggressive immunomodulatory therapy.

The initial part of the schematic details a four-pronged therapeutic plan, a strategy that can be understood as a coordinated attack on the different facets of vitiligo pathogenesis. This was not a random assortment of treatments but a carefully constructed regimen where each component played a distinct, synergistic role. The cornerstone of the intervention, as outlined in Figure 4, was Systemic Immunomodulation with an oral dexamethasone minipulse (OMP). This was the "fire extinguisher" deployed to rapidly quell the aggressive, systemic inflammatory process that was driving the disease. The choice of a potent glucocorticoid like dexamethasone was critical to halt the ongoing destruction of melanocytes. Its mechanism of action is profound and multifaceted; it induces apoptosis in the autoreactive CD8+ T-cells that are the primary executioners of melanocytes. Furthermore, it acts at the genomic level to suppress the production of key pro-inflammatory cytokines, including interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α), by inhibiting transcription factors like NF-κB. The "minipulse" regimen—administering the dose on only two consecutive days per week—is a strategic approach designed to deliver a powerful immunosuppressive effect sufficient to break the cycle of inflammation while significantly minimizing the cumulative toxicity and adverse effects associated with long-term daily corticosteroid use. Complementing the systemic approach was Topical Immunomodulation with pimecrolimus 1% cream. This addresses the localized nature of the immune

attack directly at the site of the facial lesions. Pimecrolimus is a topical calcineurin inhibitor, and its inclusion was particularly crucial for the face, an area highly susceptible to the atrophic side effects of topical steroids. Pimecrolimus works by a different, more targeted mechanism. It blocks the action of calcineurin, a key enzyme in the T-cell activation pathway. This inhibition prevents the dephosphorylation of the Nuclear Factor of Activated T-cells (NFAT), a transcription factor that is essential for the production of Interleukin-2 (IL-2). Since IL-2 is the primary cytokine responsible for T-cell proliferation, pimecrolimus effectively dampens the local expansion of the pathogenic T-cell population without inducing skin atrophy. This provided sustained, safe, and targeted anti-inflammatory control on the sensitive facial skin. Once the inflammatory assault was being suppressed, the therapeutic focus could pivot to regeneration, which was addressed by Phototherapy. As indicated in Figure 4, Narrowband UVB (NB-UVB) at a wavelength of 311 nm was employed, which is considered the gold standard for inducing repigmentation. NB-UVB's efficacy is elegantly dual-action. First, it has its own immunomodulatory effects, promoting the apoptosis of skin-infiltrating pathogenic T-cells and, importantly, inducing the formation of T-regulatory cells (Tregs). These Tregs help to restore a state of local immune tolerance, creating a "safe space" for new melanocytes to survive. Second, and most critically for repigmentation, NB-UVB acts as a direct biostimulant. It activates the dormant melanocyte stem cells residing in the hair follicle bulge, prompting them to proliferate, differentiate, and migrate out into the surrounding depigmented epidermis to repopulate it with functional pigment-producing cells. Finally, the schematic includes Adjuvant Therapy, acknowledging that a holistic approach is necessary. The inclusion of oral zinc supplementation addresses the oxidative stress hypothesis of vitiligo, as zinc is a vital cofactor for antioxidant enzymes. The mandatory use of a broad-spectrum, high-SPF sunscreen is also critical. It not only prevents sunburn on the vulnerable,

depigmented skin but also minimizes the generation of UV-induced reactive oxygen species (ROS), which can act as a potent trigger for the inflammatory cascade, thereby helping to prevent future flares.

The lower portion of Figure 4 provides the definitive evidence of the success of this multi-modal strategy, contrasting the patient's baseline state with the outcome at six months. This longitudinal data transforms the therapeutic plan from a theoretical exercise into a validated success story. The most dramatic and clinically significant change is seen in the VIDA Score, which plummeted from a highly active +4 at baseline to a completely stable 0 at six months. This is the primary endpoint for any therapy aimed at unstable vitiligo and represents a total cessation of disease progression. It confirms that the immunomodulatory components of the therapy were successful in halting the autoimmune attack. No new lesions appeared, and existing ones stopped expanding. Concurrently, the VASI Score, which measures the extent of depigmentation, showed a significant improvement, decreasing from 1.0 to 0.6. This represents a 40% reduction in the affected area, a degree of repigmentation that is both statistically and cosmetically significant, especially on the face. This demonstrates the efficacy of the regenerative component of the therapy, primarily the NB-UVB, which could only work effectively once the inflammatory environment was controlled. The "Summary of Clinical & Dermoscopic Improvements" section of Figure 4 further elucidates the success story. The complete stabilization of the disease (VIDA 0) is the foundational achievement. The significant repigmentation, occurring in a classic perifollicular pattern, is the visible proof of the regeneration of pigment from the hair follicle reservoirs. Critically, the summary notes the complete resolution of the dermoscopic signs of inflammation (the pinkish background and telangiectasias), providing microscopic confirmation that the underlying immune battle had ceased. Perhaps most elegantly, it highlights that the dermoscopic signs of progression, such as the reversed pigment network, were replaced by signs of repigmentation. This illustrates a complete reversal of the disease's momentum at the cellular level, from a state of active destruction to one of active healing and recovery. Figure 4 serves as a powerful visual narrative. It details a scientifically sound therapeutic plan that was designed to comprehensively target the known pathways of vitiligo pathogenesis. It then presents clear, quantitative, and qualitative evidence that this strategy was profoundly successful, leading to complete disease stabilization, significant cosmetic improvement, and a restoration of hope for the patient. This complete, longitudinal dataset—from the initial paradoxical presentation to the post-treatment clinical and dermoscopic evidence of both disease stabilization and significant repigmentation—provides a comprehensive narrative. It validates the initial diagnostic assessment of high activity and demonstrates the positive outcome of the evidence-based, aggressive therapeutic strategy that was employed.

3. Discussion

This case report provides a detailed, longitudinal analysis of the clinical reasoning, diagnostic process, and therapeutic management of a patient presenting with the common yet challenging paradox of low-extent but high-activity facial vitiligo.[11] The discussion moves beyond a simple case description to critically analyze the interplay between clinical signs and underlying pathophysiology, justify the therapeutic decisions made in the face of viable alternatives, and explore the broader implications of these findings for the modern management of vitiligo. For decades, the clinical approach to vitiligo was dominated by a focus on the "white patch"—the end result of melanocyte destruction. This case, however, powerfully illustrates the modern paradigm of active vitiligo as a fundamentally inflammatory disease. The patient's initial presentation with "reddish-white" macules was not an incidental feature but a crucial clinical signpost pointing to an active, immune-mediated battle in the skin.[12]

Therapeutic Intervention and 6-Month Longitudinal Follow-up

Multi-Modal Therapeutic Intervention

Systemic Immunomodulation

Oral Dexamethasone Minipulse (OMP) to rapidly halt the systemic inflammatory attack.

Topical Immunomodulation

Pimecrolimus 1% cream for targeted, steroid-sparing anti-inflammatory effect on facial skin.

Phototherapy

Narrowband UVB (NB-UVB) to stimulate melanocyte stem cells and induce repigmentation.

Adjuvant Therapy

Oral Zinc supplementation and mandatory use of broad-spectrum SPF 50+ sunscreen.

6-Month Follow-up

Longitudinal Follow-up at 6 Months

Baseline State

VIDA Score	**+4**
VASI Score	**1.0**

6-Month Outcome

VIDA Score	**0**
VASI Score	**0.6**

Summary of Clinical & Dermoscopic Improvements

- Disease progression halted; complete stabilization achieved (VIDA 0).
- Significant repigmentation (40% improvement) with a classic perifollicular pattern.
- Dermoscopic signs of inflammation (pinkish background, telangiectasias) completely resolved.
- Dermoscopic signs of progression (reversed pigment network) replaced by signs of repigmentation.

Figure 4. Therapeutic intervention and 6-month longitudinal follow-up.

Our dermoscopic findings of a pinkish background and prominent telangiectasias were not merely confirmatory; they provided an in vivo window into this battlefield, allowing for the visualization of the morphological consequences of a complex molecular cascade. This inflammatory signature is now understood to be orchestrated primarily by the interferon-gamma (IFN-γ) signaling axis. In a genetically susceptible individual, various triggers—in this case, plausibly UV radiation and minor mechanical trauma—can lead to cellular stress in melanocytes.[13] This stress causes them to release damage-associated molecular patterns (DAMPs) and upregulate the expression of MHC-I molecules, making them more visible to the immune system. This initial stress response activates the innate immune system, including Natural Killer (NK) cells and plasmacytoid dendritic cells, which can initiate an

early, non-specific attack and release Type I interferons. This innate activation serves as a critical bridge to the adaptive immune response. Autoreactive, melanocyte-specific CD8+ cytotoxic T-lymphocytes (CTLs) are recruited to the skin. Once they recognize their target antigens on melanocytes, these CTLs release large amounts of IFN-γ. IFN-γ is the master cytokine in vitiligo pathogenesis. It binds to its receptors on surrounding keratinocytes, triggering a signaling cascade that results in the massive production of the chemokines CXCL9 and CXCL10. These chemokines are potent chemoattractants for T-cells expressing the CXCR3 receptor. This creates a devastating positive feedback loop: infiltrating CTLs release IFN-γ, which induces keratinocytes to produce CXCL9/10, which in turn recruits even more CXCR3+ CTLs to the site, amplifying the inflammatory response and leading to widespread melanocyte apoptosis. The vasodilation and increased vascular permeability driven by other co-released cytokines, such as TNF-α, manifest dermoscopically as the telangiectasias and pinkish background we observed.[14] Therefore, what we "deciphered" with the dermoscope was the visible signature of the IFN-γ/CXCL10/CXCR3 axis in full operation.

The "Convergence Theory" posits that vitiligo arises not from a single defect but from the confluence of multiple intrinsic and extrinsic factors that collectively overwhelm melanocyte resilience. This case provides a compelling, real-world model for this theory. First, an intrinsic predisposition is assumed, representing the genetic foundation that makes her melanocytes inherently more vulnerable. Second, this vulnerability was likely exploited by chronic environmental stressors. Her history of frequent, unprotected sun exposure is a key factor. UV radiation is a potent inducer of reactive oxygen species (ROS) in the skin.[15] In individuals with a potential constitutional defect in their antioxidant systems (low catalase activity), this leads to a state of severe oxidative stress. This excess ROS can directly damage melanocyte DNA and membranes, and crucially, it triggers the release of DAMPs like HSP70, which are powerful signals for the innate immune system. Third, the patient's habit of rubbing her face with a towel represents a source of repetitive, low-grade mechanical trauma. This could contribute via the Koebner phenomenon or by promoting melanocytorrhagy—the physical detachment of intrinsically "unsticky" melanocytes from the basement membrane. This detachment further fuels the immune response by releasing cellular contents and antigens. In this model, these three elements—intrinsic vulnerability, oxidative stress from UV, and mechanical stress—converged to create a "perfect storm." They initiated a state of chronic melanocyte stress, which activated both innate and adaptive immune pathways, culminating in the clinically apparent, rapidly progressive inflammatory vitiligo we observed.[16]

The decision to initiate an aggressive, multi-modal therapy in a patient with a VASI score of only 1 warrants a critical defense, as a more conservative, stepwise approach is a valid alternative. One could argue for starting with high-potency topical therapy (steroids or TCIs) combined with NB-UVB, reserving systemic agents for non-responders. However, our clinical reasoning was driven by a careful weighing of the evidence, which pointed overwhelmingly towards a highly aggressive disease course that would likely outpace the effects of topical therapy alone. The patient provided a clear and credible history of rapid progression. Ignoring this subjective but powerful data point would have been a disservice. The VIDA score, while based on recall, is a validated tool designed to capture exactly this type of aggressive activity.[17] The dermoscopic confirmation of leukotrichia was a critical factor. This finding indicates that the inflammatory process was not merely superficial but was deep enough to destroy the vital melanocyte stem cell reservoir in the hair follicles. This is a sign of severe disease, and once the follicular reservoir is lost, the potential for cosmetically acceptable repigmentation is drastically reduced. Delaying systemic therapy risked the further, irreversible loss of these reservoirs in other areas. This was the deciding factor. The dermoscopic findings were not

subtle. The combination of a diffuse pinkish background, prominent telangiectasias, and a classic reversed pigment network provided objective, real-time evidence of a significant underlying inflammatory process.[18] In this context, the low VASI score was interpreted not as a sign of mild disease, but as a snapshot of a very early, yet explosive, process. We concluded that the risk of allowing this "wildfire" to spread while waiting for topical agents to take effect was greater than the risk associated with a short course of oral minipulse steroid therapy. While initiating all therapies at once does create methodological confounding, from a clinical and ethical standpoint, the primary goal was to secure the best possible outcome for the patient. We chose to deploy the most effective tools simultaneously to maximize the chance of halting progression and preserving the follicular reservoir in a cosmetically sensitive area. The successful outcome at 6 months, with disease stabilization and significant repigmentation, provides post-hoc support for this aggressive initial strategy.

The 6-month follow-up provides the crucial denouement to this case. The clinical improvement, with a reduction in the VIDA score to 0 and a 40% improvement in the VASI score, was gratifying.[19] However, it was the follow-up dermoscopy that told the most compelling story of therapeutic success. The complete resolution of the pinkish background and telangiectasias objectively demonstrated the efficacy of the OMP and topical pimecrolimus in extinguishing the inflammatory fire. This confirmed that the vascular pattern was indeed a dynamic marker of the underlying immune activity. More importantly, the pattern of repigmentation was classic and informative. The appearance of numerous perifollicular pigmented dots is the textbook sign of repigmentation originating from the hair follicle reservoir.[20] This indicates that our timely intervention was successful in preserving the melanocyte stem cells in many of the affected follicles. The NB-UVB therapy played a key role here, providing the necessary stimulus for these stem cells

to proliferate, differentiate, and migrate out to repopulate the surrounding depigmented epidermis.

The process begins with the Convergence of Triggers, which are the initial insults that set the pathological cascade in motion. The first element is an intrinsic Genetic Predisposition. This does not mean vitiligo is a simple inherited disease, but rather that the patient was likely born with melanocytes that are inherently more vulnerable, less resilient to stress, and more prone to expressing the "danger signals" that can attract immune attention. This underlying susceptibility is the fertile ground upon which environmental factors can act. In this specific case, two key environmental triggers from the patient's history were identified. The first is UV Radiation. The patient's history of frequent, unprotected sun exposure is not merely an incidental fact; it is a direct pathogenic contributor. UV light is a potent generator of reactive oxygen species (ROS) in the skin, leading to a state of severe oxidative stress. In a genetically predisposed individual whose melanocytes may already have a diminished capacity to handle ROS, this UV-induced oxidative stress causes direct cellular damage, leading to dysfunction and apoptosis. The second trigger is Mechanical Trauma. The patient's habit of vigorously rubbing her face with a towel represents a form of chronic, low-grade physical stress. This can induce the Koebner phenomenon or contribute to what is known as melanocytorrhagy—a state where intrinsically fragile melanocytes detach from the basement membrane, further contributing to their demise. As depicted in Figure 5, these disparate triggers do not act in isolation; they converge upon a Central Pathological Event: Melanocyte Stress. This is the critical tipping point where the damaged melanocytes transition from being quiet residents of the epidermis to becoming active participants in their own destruction. Under this combined stress, the melanocytes begin to release damage-associated molecular patterns (DAMPs), which are endogenous molecules that signal injury and danger to the immune system.

Pathophysiological Cascade and its Clinical Manifestations in the Patient

1. Convergence of Triggers (Based on Patient History)

Genetic Predisposition	**UV Radiation**	**Mechanical Trauma**
Inherently vulnerable melanocytes susceptible to stress.	Causes oxidative stress (ROS), damaging melanocytes.	Face rubbing promotes melanocytorrhagy (detachment).

↓

2. Central Pathological Event: Melanocyte Stress

Triggers converge, causing melanocytes to release Damage-Associated Molecular Patterns (DAMPs) and express stress antigens, initiating an immune alert.

↓

3. The Autoimmune Cascade

A. Innate Immune Activation
DAMPs activate innate cells (NK cells, pDCs), leading to initial inflammation and Type I IFN release.

B. Adaptive Immune Activation
Autoreactive CD8+ T-cells recognize stress antigens on melanocytes and are activated.

C. The IFN-γ Feedback Loop
Activated CD8+ T-cells release IFN-γ. This stimulates keratinocytes to produce chemokines (CXCL9, CXCL10), which recruit more CXCR3+ T-cells, amplifying the attack.

↓

4. Clinical & Dermoscopic Manifestations (Case Findings)

Inflammation & Vasodilation	**Progressive Destruction**	**Follicular Reservoir Damage**	**Complete Melanocyte Loss**
Cytokine release causes increased blood flow, manifesting as **Erythema** (pinkish background) and **Telangiectasias**.	Preferential attack on interfollicular melanocytes leads to the **Reversed Pigment Network**.	Intense, deep inflammation destroys melanocyte stem cells, resulting in **Leukotrichia**.	The final result of the cytotoxic attack is complete depigmentation, seen as **Whitish Structureless Areas**.

Figure 5. Pathophysiological cascade and its clinical manifestations in the patient.

Simultaneously, they begin to express unique stress antigens on their surface. Together, these actions serve as a powerful "immune alert," effectively sending out a distress call that mobilizes the body's defense systems. This alert initiates the autoimmune cascade, a sophisticated, multi-stage process that is the core engine of vitiligo. The first responders belong to the innate immune system. The DAMPs released by the stressed melanocytes activate innate immune cells like natural killer (NK) cells and plasmacytoid dendritic cells (pDCs). This innate immune activation results in an initial wave of non-specific inflammation and the release of Type I interferons, further amplifying the danger signal. This innate response serves as a crucial bridge, setting the stage for the more specific and destructive adaptive immune

response.[19] In this second phase, adaptive immune activation, autoreactive CD8+ T-cells—specialized "killer" cells that have been pre-programmed to recognize the stress antigens now displayed by the melanocytes—are activated and recruited to the skin. The final and most devastating step of the cascade is the IFN-γ feedback loop. The activated CD8+ T-cells that have infiltrated the skin release massive quantities of a powerful cytokine called interferon-gamma (IFN-γ). This IFN-γ orchestrates a powerful amplification of the attack. It stimulates the surrounding skin cells (keratinocytes) to produce a pair of chemokines, CXCL9 and CXCL10. These chemokines act as highly specific homing beacons, attracting even more pathogenic T-cells that possess the CXCR3 receptor.[20] This creates a vicious, self-perpetuating cycle: T-cells arrive, release IFN-γ, which causes the release of more chemokines, which in turn summon more T-cells. This exponential amplification of the immune assault is what drives the rapid progression of the disease seen in this patient. Figure 5 masterfully connects this complex molecular cascade to the actual clinical and dermoscopic findings observed in the patient, illustrating how each sign is a direct physical manifestation of a specific pathological event. The massive release of cytokines during the immune attack causes inflammation & vasodilation, which is seen clinically as Erythema (redness) and dermoscopically as a pinkish background with fine Telangiectasias. The direct cytotoxic T-cell attack on the melanocytes leads to their death, but this destruction is not uniform. The Progressive Destruction often occurs preferentially in the more exposed interfollicular areas, resulting in the specific dermoscopic pattern of a Reversed Pigment Network at the expanding border of the lesion. When the inflammatory attack is particularly severe, it can cause Follicular Reservoir Damage, destroying the vital melanocyte stem cells in the hair follicle and leading to leukotrichia, a sign of deep damage and poor prognosis for repigmentation. Ultimately, the end result of this sustained cytotoxic process is complete melanocyte loss, which is visualized clinically as a depigmented white patch and dermoscopically as a barren, whitish structureless area. This final stage represents the visible scar left behind by the complex immunological battle detailed throughout the schematic.

4. Conclusion

This longitudinal case report illustrates the clinical reasoning required to manage the common but challenging scenario of low-extent, high-activity vitiligo. It underscores the profound limitations of relying on a single metric, such as the affected surface area, and makes a strong case for a more holistic and integrated diagnostic process. We have demonstrated that when a patient's history of rapid progression is corroborated by objective dermoscopic evidence of inflammation—even in the face of a low VASI score—it constitutes a clear mandate for prompt and decisive immunomodulatory therapy. While acknowledging the inherent limitations of a single case report, this experience suggests that dermoscopy is not merely an adjunctive tool but can function as a pivotal biomarker to resolve clinical paradoxes and guide therapeutic strategy. By learning to decipher the subtle language of inflammation written on the skin, clinicians can move beyond simply reacting to established depigmentation and instead proactively manage vitiligo as the complex, dynamic autoimmune disease it is, thereby altering its trajectory and offering our patients a more hopeful path towards disease control and repigmentation. Further prospective studies are warranted to validate this integrated approach in larger patient cohorts.

5. References

1. Du Z, Wang H, Gao Y, Zheng S, Kou X, Sun G, et al. Exploring the potential molecular mechanism of Sijunzi decoction in the treatment of non-segmental vitiligo based on network pharmacology and molecular docking. Clin Cosmet Investig Dermatol. 2023; 16: 821–36.

2. Silpa-Archa N, Likittanasombat S, Apinuntham C, Pruksaeakanan C, Charoenpipatsin N, Chaiyabutr C, et al. The efficacy of bimatoprost ophthalmic solution combined with NB-UVB phototherapy in non-segmental and segmental vitiligo: a single-blind randomized controlled study. Sci Rep. 2023; 13(1): 6438.

3. Wang Y, Lin M, Huang F, Jia R, Xu W, He Q, et al. Efficacy and safety of fire needle therapy in treating non-segmental stable vitiligo: a randomized self-controlled clinical trial. J Cosmet Dermatol. 2024; 23(10): 3335–46.

4. Satkunanathan S, Boshra M, Chang J, Bose R. Rapid resolution of non-segmental vitiligo in a patient treated with abrocitinib: a case report. SAGE Open Med Case Rep. 2024; 12: 2050313X241231527.

5. Kang C. Ruxolitinib cream 1.5%: a review in non-segmental vitiligo. Drugs. 2024; 84(5): 579–86.

6. Kaur N, Kaur J, Sharma S. Novel combination of NB-UVB phototherapy with bFGF-related decapeptide 0.1% and CO_2 laser in the treatment of stable, non-segmental vitiligo. Port J Dermatol Venereol. 2024; 82(2).

7. Zartab H, Aflatoonian M, Shamsi-Meymandi S, Pardakhty A, Isazadeh A, Firooz A, et al. Assessing effectiveness of adding niosomal atorvastatin 1% ointment to topical calcineurin inhibitor treatment in non-segmental vitiligo. J Cosmet Dermatol. 2024; 23(6): 2103–8.

8. Passeron T, Ezzedine K, Hamzavi I, van Geel N, Schlosser BJ, Wu X, et al. Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study. EclinicalMedicine. 2024; 73(102655): 102655.

9. Agner ML, Parraga SP, Arkhipenko ZM, Pichardo RO, McMichael AJ, Feldman SR. Evaluation of ruxolitinib cream 1.5% as an at-home therapy for repigmentation in non-segmental vitiligo. Expert Rev Clin Immunol. 2024; 20(7): 695–702.

10. Treatment of non-segmental vitiligo in the resistant localizations with NB-UVB after application of erbium: YAG laser plus pimecrolimus in comparison with NB-UVB after application of erbium: YAG laser plus topical steroid. Egypt J Hosp Med. 2024; 96(1): 3352–64.

11. Mansouri P, Rahbar M, Nilforoushzadeh MA, Shati M, Amirkhani MA. Fractional CO_2 laser versus microneedling combined with narrowband ultraviolet and topical steroid for treating non-segmental vitiligo in treatment-resistant localizations: a comparative randomized clinical trial study. J Lasers Med Sci. 2024; 15: e38.

12. Gohary YM, Abdelhady EG, Sayed AN, Rashed LA, Kamel HAER. Clinical study of Wnt inhibitory factor-1 expression and its association with disease severity in non-segmental vitiligo. Beni-Suef Univ J Basic Appl Sci. 2024; 13(1).

13. Hu Z, Lu L, Feng J, Song H, Zhang S, Yang L, et al. Low-dose baricitinib plus narrow-band ultraviolet B for the treatment of progressive non-segmental vitiligo: a prospective, controlled, open-label study. Pigment Cell Melanoma Res. 2025; 38(1): e13209.

14. Hussien MF, Bassiouny DA, El Maadawi ZM, Soliman AM, Al-Boani AM, El Zawahry YB. Estimation of melanocytic count in different donor areas in non-segmental vitiligo before and after narrow band ultraviolet B phototherapy. Egypt J Dermatol Venerol. 2025; 45(1): 61–7.

15. Zhou L, Chen C. Efficacy and safety of fractional CO2 laser combined with 308 nm excimer laser in non-segmental vitiligo: a meta-analysis with trial sequential analysis. J Cosmet Laser Ther. 2025; 27(3): 87–94.

16. Abdelaziz RK, Mohammed HAK, Fouda I. Efficacy of topical tacrolimus 0.03% ointment in combination with microneedling versus topical phenytoin 2% cream in combination with microneedling for the treatment of non-segmental facial vitiligo. Arch Derm Res. 2025; 317(1): 671.

17. Sharma A, Gupta V, Bhatia S, Upadhyay A, Challa A, Gupta S. Apremilast versus betamethasone oral mini-pulse in the treatment of progressive non-segmental vitiligo: a randomised pilot trial. Indian J Dermatol Venereol Leprol. 2025; 91(3): 398–401.

18. Lestani V, D'Odorico I, Guglielmo A, Errichetti E, Stinco G. Development of multiple flat warts during treatment with ruxolitinib 1.5% cream for non-segmental vitiligo: a case report. Int J Dermatol. 2025.

19. Qi Z, Zhang L, Chang S, Guo S, Zhang Y, Jiang G. 308 nm excimer laser combined with JAK inhibitors for adult localized non-segmental vitiligo: a multicenter randomized controlled trial. Int J Dermatol. 2025.

20. Özgün Geçer M, Kaya G. Clinical, histological, and immunohistochemical signatures of non-segmental vitiligo: a case-control analysis of Melan-A expression and CD8[+] T-cell infiltration. Sci Rep. 2025; 15(1): 27425.